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ABSTRACT
Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with a median
survival of 14.6 months. Recent efforts have focused on identifying clinically relevant subgroups to
improve our understanding of pathogenetic mechanisms and patient stratification. Concurrently, the
role of immune cells in the tumor microenvironment has received increasing attention, especially T cells
and tumor-associated macrophages (TAM). The latter are a mixed population of activated brain-resident
microglia and infiltrating monocytes/monocyte-derived macrophages, both of which express ionized
calcium-binding adapter molecule 1 (IBA1). This study investigated differences in immune cell subpo-
pulations among distinct transcriptional subtypes of GBM. Human GBM samples were molecularly
characterized and assigned to Proneural, Mesenchymal or Classical subtypes as defined by NanoString
nCounter Technology. Subsequently, we performed and analyzed automated immunohistochemical
stainings for TAM as well as specific T cell populations. The Mesenchymal subtype of GBM showed
the highest presence of TAM, CD8+, CD3+ and FOXP3+ T cells, as compared to Proneural and Classical
subtypes. High expression levels of the TAM-related gene AIF1, which encodes the TAM-specific protein
IBA1, correlated with a worse prognosis in Proneural GBM, but conferred a survival benefit in
Mesenchymal tumors. We used our data to construct a mathematical model that could reliably identify
Mesenchymal GBM with high sensitivity using a combination of the aforementioned cell-specific IHC
markers. In conclusion, we demonstrated that molecularly distinct GBM subtypes are characterized by
profound differences in the composition of their immune microenvironment, which could potentially
help to identify tumors amenable to immunotherapy.
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Introduction
Glioblastoma (GBM) is the most common and aggressive
malignant primary brain tumor in adults. It is characterized
by diffuse infiltration of high-grade glioma cells into the brain
parenchyma and resistance to standard of care.1–3 Despite
treatment regimens consisting of surgical resection, che-
motherapy and radiotherapy, patients have median survival
times of only 14.6 to 20.9 months.4,5 Thus, a greater under-
standing of GBM pathogenesis will provide insight for
informed treatment strategies.
Previously, comprehensive analyses of gene expression
profiles have identified clinically meaningful subgroups to
facilitate the study of this heterogeneous disease.6–9 The
Cancer Genome Atlas (TCGA) originally proposed four sub-
types, referred to as Proneural (PN), Mesenchymal (MES),
Classical (CL), and Neural (NL) .8 However, following robust
gene expression classification, only three subtypes, PN, MES,
and CL, are currently recognized, each with its own charac-
teristic genomic alterations.10–12 Although multiple subtypes
can co-exist within a single tumor, both at the regional and
single-cell level,13 the designated subtypes reflect the domi-
nant transcriptional program of a specific tumor.
In parallel with efforts to define GBM genomics, transcrip-
tomics, and cell signaling within the tumor cell population,
other investigations have attempted to more fully characterize
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its diverse cellular composition. GBM is a dynamic ecosystem
composed of neoplastic and non-neoplastic cells, which
together form the tumor microenvironment and play
a significant role in GBM pathogenesis. 14,15 Particular
emphasis has been placed on immune system constituents,
especially tumor-associated macrophages (TAM). This mixed
population of activated brain-resident microglia and infiltrat-
ing bone marrow-derived macrophages constitutes up to 45%
of cells within GBM and has been shown to engage in reci-
procal interactions with neoplastic cells to promote tumor
growth and progression.16–20 Although these cell types origi-
nate from distinct sources – with progenitor cells of microglia
migrating into the brain during embryonic brain develop-
ment, and macrophages derived from peripheral monocytes
only infiltrating the brain as a result of tissue injury – they
both express ionized calcium-binding adapter molecule 1
(IBA1), a protein involved in membrane ruffling and phago-
cytosis that is used to visualize both cell types.21–25 With the
advent of immunotherapeutic strategies for GBM, T cells have
also been subject to increasing scrutiny.26–28 Previous studies
have found increased expression of immune response-related
genes in MES GBM,8,29,30 yet its biological relevance remains
unclear. The main aim of this study is to investigate whether
the PN, MES and CL subtypes of GBM differ with respect to
the presence of TAM and distinct T cell subpopulations.
Materials and methods
Tissue samples and pathological appraisal
Human formalin-fixed, paraffin-embedded (FFPE)GBMsamples,
post-mortem brain specimens, and de-identified clinical informa-
tion were provided by Emory University, Memorial Sloan
Kettering Cancer Center, Uppsala University, and the University
of Washington Medical Center following ethical approval by
institutional review boards. Pathologists graded and diagnosed
the tissue based on the 2007 World Health Organization
Classification of Tumors of the Central Nervous System.31 The
2016 classification had not yet been published at the time work on
this project commenced. Both primary and recurrent tumors were
used for this study. All tissue samples were anonymized.
Gene expression profiling using nanostring ncounter
technology
The procedure to identify GBM subtype based on gene expression
levels has been described elsewhere in detail.32–34 Briefly, RNAwas
extracted from tumor samples and expression levels were analyzed
by NanoString nCounter Technology (NanoString Technologies,
Seattle, U.S.A.) using custom-made probes for 152 genes from the
original GBM_2design for the training (32 in total, 27GBM, and 5
control brains) and test sets (29 GBM in total) (Supplementary
Table S1).
Immunohistochemistry (IHC)
FFPE specimens were sectioned at five-micrometers and
stained on the DISCOVERY XT platform (Ventana Medical
Systems, Inc., Tucson, U.S.A). TAM and microglia were
identified using antibodies against IBA1. Antibodies targeting
CD3 and CD8 stained the entire T cell population and cyto-
toxic T cells, respectively. Regulatory T cells were stained by
antibodies against forkhead box P3 (FOXP3). Due to the lack
of a validated antibody, the CD4+ T cell number was esti-
mated to be the difference between the CD3+ and CD8+ T cell
numbers according to published protocol.35 In six cases, the
number of CD8+ T cells exceeded or was identical to the
number of CD3+ T cells, so that the CD4+ T cell population
was considered to be equal to the FOXP3+ T cell number,
since the latter constitutes a subpopulation of CD4+ T cells.
The following primary antibodies were used: Anti-IBA1
(1:500, rabbit polyclonal, #019–19741, Wako Pure Chemical
Ind., Ltd., Osaka, Japan); anti-human FOXP3, clone 259D
(1:100, mouse monoclonal, #320202, BioLegend, San Diego,
U.S.A); anti-human CD8, clone C8/144B (1:100, mouse
monoclonal, code M7103, Dako, Glostrup, Denmark); anti-
human CD3 (1:100, rabbit polyclonal, code A0452, Dako,
Glostrup, Denmark).
Immunofluorescent staining
Five-micrometer FFPE sections were deparaffinized and rehy-
drated before antigen retrieval was performed by heating the
sections in citrate solution (Vector Shield) at 93°C for 15 min.
The sections were then treated with 0.3% Triton in PBS and
blocked with 3% normal donkey serum in PBS for 30 min at
room temperature. Primary antibodies targeting CD3 (1:100,
rabbit polyclonal, code A0452, Dako, Glostrup, Denmark) and
CD2 (1:100, mouse monoclonal, code NBP2-32814,
Centennial CO, USA) were incubated with the sections for
90 min at room temperature. Secondary antibodies donkey-
anti-rabbit-Alexa 488 and donkey-anti-mouse-Alexa 568
(Invitrogen) at a dilution of 1:500 in PBS were applied to
the sections for 1h at room temperature. DAPI (Sigma) was
used for nuclear counterstaining. Images were acquired on
a Leica DM2500 microscope.
Image acquisition
The Nanozoomer 2.0HT (Hamamatsu Photonic K.K.,
Hamamatsu, Japan) whole slide scanner was utilized to digi-
talize the stained tissue sections. Image analysis was per-
formed using Fiji.36 Images were captured at 20x
magnification, representing an area of 0.3828 mm2 and
0.4263 mm2, depending upon the screen used for quantifica-
tion. Owing to the high number of TAM in GBM, it was not
possible to consistently identify those cells individually.
Therefore, for IBA1, the percentage of stained area per field
was analyzed, whereas the number of cells per field was
quantified for CD3, CD8 and FOXP3. The total amount of
representative images obtained from each tissue section ana-
lyzed with Fiji was standardized based on overall tumor area,
but so far as possible, at least five images were captured. In
order to account for heterogeneity within individual samples,
every tissue section was subdivided into different regions.
Each region was subsequently attributed a percentage of the
total number of images per section on the basis of its relative
size. Investigators were blinded as to the subtype of the GBM
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samples during the quantification process. Necrotic and peri-
tumor areas were not included. Pixel width of the images was
454 nanometers and final values were standardized to an area
of one mm2.
Microglia/macrophage shape analysis
Four tumors with adjacent non-tumor tissue were stained for
IBA1+ cells, including microglia in the healthy brain and
TAM. Three images were taken in each of the regions of
interest, namely the tumor, peri-tumor, and non-tumor
areas. The peri-tumor area was defined as a field in which
half of the area resembled tumor and the other half resembled
non-tumor tissue based on cellular density and composition,
as well as macrophage morphology. In each field, the number
of primary processes per IBA1+ cell was counted and then
averaged as a measure of cell activation. Plot profiles display-
ing changes in staining intensity in four adjacent fields (one
non-tumor, one peri-tumor, and two tumor) were generated
for each of the four samples using Fiji. The mean and stan-
dard deviation of the relative intensity were plotted with
MatLab software (The MathWorks, Inc., Natick, U.S.A).
TCGA analysis
Expression levels and survival data corresponding to the genes
of interest were obtained from the cBioPortal for Cancer
Genomics (Cancer Study: Glioblastoma Multiforme (TCGA,
Provisional), Genomic Profiles: mRNA Expression z-Scores
(microarray)) in August of 2016, which provides tools for
the analysis and visualization of TCGA datasets.37,38 All pri-
mary GBM with complete gene expression and subtype infor-
mation were analyzed. In total, 357 samples were included, of
which 69 were PN, 106 MES, and 101 CL. Of the remaining
samples, 55 demonstrated a NL signature and 26 displayed
a glioma-CpG island methylator phenotype (G-CIMP). For
the subtype-specific analyses, G-CIMP-positive and NL
tumors were excluded. The GBM subtype classification was
described by Verhaak et al. 8
Mathematical prediction model of GBM subtypes
The markers IBA1, CD3, FOXP3 and CD8 were combined to
create an empirically-derived, threshold-based GBM subtype
prediction model. Given the three-level outcome with three
possible GBM subtypes, a multinomial model, which is an
extension of a logistic regression model with more than two
outcomes, was fit for the training set of 29 samples. A set of
two independent binary regressions were fit, using the sub-
type PN as the reference. Parameter estimates were found by
solving for three equations: the two binary regression equa-
tions (below) and the equation: P(CL) + P(MES) + P(PN) = 1,
where P(CL) is the probability of Classical subtype, P(MES) is
the probability of Mesenchymal subtype, and P(PN) is the
probability of Proneural subtype. Using a test set of 21 sam-
ples and the parameter estimates from the multinomial
model, predicted probabilities for each subtype were gener-
ated for each sample. The subtype with the highest predicted
probability for a given sample was considered as the predicted
subtype for that sample. For example, if a sample’s set of
predicted probabilities was P(CL) = 0.65, P(MES) = 0.2,
P(PN) = 0.15, then that sample was classified as a CL subtype
based on the model. The sensitivity and specificity for each
subtype, along with 95% confidence intervals, were reported
(Supplementary Tables S3, S4). P-values from the multinomial
model were also reported.
Equations: Set of binary regression equations estimated
from the multinomial model:
log
PðCLÞ
PðPNÞ
 
¼ 0:7722þ 0:0350  IBA1 0:0067  FOXP3
þ 0:0161  CD3 0:0040  CD8
log
PðMESÞ
PðPNÞ
 
¼ 8:8873þ 0:5496  IBA1þ 0:2417
 FOXP3þ 0:0311  CD3 0:0594  CD8
Statistical analysis
Graphs were created with GraphPad Prism 6.0b and 7.04
(GraphPad Software Inc., La Jolla, U.S.A). One-way ANOVA
and Tukey´s multiple comparisons tests were used to compare
more than two groups. Analyses involving low sample num-
bers were performed using Dunn’s multiple comparisons test
and a two-tailed Mann-Whitney U test. Correlations were
analyzed with the Pearson correlation coefficient (r). The Log-
rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test
were performed for survival analyses. Significance levels
were indicated as follows: ns (not significant); * (P < .05); **
(P < .01); *** (P < .001); **** (P < .0001). Details pertaining to
individual graphs are included in the figure legends.
Results
Human gene expression data reveal differential immune
profiles among GBM subtypes and indicate distinct
effects on survival
Gene expression data corresponding to the immune cell markers
of interest were obtained fromTCGA and surveyed for differences
among the establishedGBM subtypes PN,MES andCL (Figure 1).
Genes analyzed were AIF1 (encoding IBA1), CD8B (beta-chain of
CD8), CD4 (CD4), FOXP3 (FOXP3), andCD3G (gamma chain of
CD3). We identified a significant upregulation of the macrophage
marker AIF1, CD3G and CD4 in MES GBM. To further evaluate
the correlative biological significance of increased immune cells in
MES tumors, levels for each marker were split into groups of high
and low expression in order to identify differences in overall
survival.
In PN GBM, AIF1 was the only gene to have an impact on
survival. High AIF1 levels were associated with a significantly
worse prognosis in patients with PN tumors compared to those
PN GBM with low expression (median survival high AIF1:
7.80 months, low AIF1: 10.56 months) (Supplementary Fig. S1).
Conversely, in MES GBM, high expression of AIF1 conferred
a survival benefit, with median survival lengths in the high-AIF1
cohort being almost twice as long (high AIF1: 14.36 months, low
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AIF1: 7.31 months) (Figure 2(a)). In the MES subtype, high
expression of the T cell marker CD3G was also prognostically
beneficial (median survival high CD3G: 14.36 months, low
CD3G: 10.43 months) (Supplementary Fig. S2). No significant
survival differences were observed in CL tumors (Supplementary
Fig. S3).
When all GBM, including those classified as NL and
G-CIMP-positive, were combined, high expression levels of
FOXP3 and CD3G were associated with improved overall
survival (Supplementary Fig. S4).
GBM is characterized by an increased presence of
immune cells compared to naïve control brains
In order to characterize immune infiltration patterns at the protein
level, 56 GBM samples were stained for IBA1, CD8, FOXP3 and
CD3. Their averages were compared to those of five control brain
samples (Supplementary Fig. S5). Quantification of the IBA1-
positive area revealed a significantly increased density of IBA1+
cells in tumor sections compared to naïve brains (mean area of all
GBM samples: 13.9%, Controls: 3.9%). Similarly, GBM was char-
acterized by higher numbers of CD8+ (20.3 cells/mm2) and
FOXP3+ (3.1 cells/mm2) T cells compared to controls (2.2 and
0.25 cells/mm2). The pan-T cell marker CD3 was also expressed
significantly higher in tumor samples (GBM: 44.6 cells/mm2,
Controls: 1.3 cells/mm2). The slightly lower number of CD3+
T cells in the naïve brains compared to the CD8+ T cell infiltration
can be explained by the extremely low levels T cell infiltrates in
healthy brains, which is likely below our methods´ threshold of
accurate quantification.
TAM are present at high levels in MES GBM
Using limited group sizes and differing methodologies to deter-
mine the tumor subtype, previous studies have proposed that
the number of IBA1+ cells is significantly higher in MES
tumors compared to the other subtypes. 39–41 In order to
discriminate between PN, CL, and MES and to increase the
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Figure 1. Box plots representing mRNA expression levels of immune-related genes in different GBM subtypes obtained from TCGA. The genes encode the following
proteins: IBA1 (AIF1), beta-chain of CD8 (CD8B), CD4 (CD4), FOXP3 (FOXP3), as well as gamma-chain of CD3 (CD3G). MES GBM shows a significant upregulation of TAM,
CD3+ and CD4+ T cell markers. Expression levels are depicted as Log2-Z-scores, with Z-scores describing the number of standard deviations that a value differs from
the mean of a given population. Sixty-nine PN, 106 MES, and 101 CL samples were included.
a
b
Figure 2. MES GBM is characterized by increased presence of TAM compared to the PN and CL subtypes. (a) Kaplan-Meier curves created using data provided by
TCGA comparing the effects of different expression levels of AIF1 on overall survival in GBM subtypes. High AIF1 expression levels confer a worse prognosis in the PN
subtype, but bestow a survival benefit in MES tumors. No effect is seen in patients with CL GBM. High and low expression levels were defined as the average of all
samples in each subtype ± 0.5 standard deviations. MC = Log-rank (Mantel-Cox) test, GBW = Gehan-Breslow-Wilcoxon test. (b) Tumor sections (scale bars represent
5 mm) and representative images of GBM samples demonstrating differential immunohistochemical IBA1 staining among distinct GBM subtypes. IBA1 labels TAM in
dark brown and nuclei are counterstained in blue using hematoxylin. Scale bar lengths correspond to 100 micrometers and 50 micrometers (inserted images). (c)
Quantification of the percentage of IBA1-positive area in the different GBM subtypes. Each data point represents the average of one tumor. PN = Proneural,
MES = Mesenchymal, CL = Classical.
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sample size per subtype, we subsequently compared the density
of TAM among the three subgroups at the protein level by
IHC. Using NanoString nCounter Technology, we found that,
out of the 56 cases of GBM, 13 were characterized as PN, 18
were assigned to the MES subtype, and 19 showed a CL profile.
Six tumors classified as G-CIMP-positive were excluded from
this analysis. Quantification in Fiji demonstrated that MES
GBM showed significantly higher levels of TAM infiltration
compared to PN and CL tumors (Figure 2(b, c)), thus corro-
borating the TCGA expression data. The results for individual
GBM samples and clinical information can be found in
Supplementary Table S2.
The MES subtype of GBM is characterized by increased T
cell levels
A similar infiltration pattern was observed for different T cell
populations (Figure 3; Supplementary Fig. S6). CD3 stains all
T cell populations and thus showed the highest numbers of all
T cell markers, with the PN and CL subtypes not differing
significantly (PN: 20.2 cells/mm2, CL: 39 cells/mm2) and MES
tumors showing markedly increased levels compared to both
(76.1 cells/mm2), confirming our observations from TCGA.
CD4+,CD8+, andFOXP3+T cells (FOXP3+ cells consist of both
CD8+/FOXP3+ and CD4+/FOXP3+) were also found at higher
densities in tumors with a MES profile as compared to PN and
CL samples. The difference in CD8+ T cell infiltration between
MES and CL GBM, however, was not significant (P = .08). CD4+
T cells were themost common (PN: 11.3,MES: 43.2, CL: 21.5 cells/
mm2), followed by CD8+ (PN: 9.4, MES: 32.9, CL: 18.6 cells/mm2)
and FOXP3+ T cells (PN: 0.7, MES: 6.3, CL: 2.2 cells/mm2).
Furthermore, significant positive correlations were found between
IBA1+ TAM and all T cell populations (Supplementary Fig. S7).
Figure 4 illustrates the differential immune cell infiltration in each
of the GBM subtypes.
Finally, we examined differences in immune cell profiles
between the six G-CIMP-positive and all non-G-CIMP tumors.
In G-CIMP-positive tumors, we observed a decreased number of
CD3+ T cells (G-CIMP: 20.2, non-G-CIMP: 47.5 cells/mm2) and
CD4+ T cells (G-CIMP: 9.5, non-G-CIMP: 26.7 cells/mm2). No
differences were seen in the infiltration of other cell types
(Supplementary Fig. S8).
Specific combinations of IHC markers can be utilized to
predict MES GBM
In order to determine the predictive nature of the immune phe-
notype for each transcriptional subtype, we then investigated the
possibility of using a combination of themarkers IBA1,CD3,CD8,
and FOXP3 to predict the subgroup of our samples. The number
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Figure 3. T cells preferentially infiltrate MES GBM. (a) Representative images depicting infiltrated CD3+, FOXP3+ and CD8+ T cells (arrows) in different GBM subtypes.
Scale bars indicate a length of 100 micrometers and 50 micrometers (inserted images). (b) Quantification of the number of CD3+ cells reveals a higher density in MES
GBM, with CD3 staining all T cells. (c) Infiltration of CD8+ T cells differs significantly between the PN and MES subtypes. CD8+ T cell numbers were also higher in MES
than CL tumors, but not significantly (p = .08). (d, e) Dot plots demonstrating FOXP3+ and CD4+ T cells appear in significantly higher numbers in MES GBM. PN and CL
GBM show similar levels of infiltration. The average of each tumor is represented by one data point.
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of CD4+ cells was estimated by subtracting the number of CD8+
cells from CD3+ cells in accordance with a published protocol35
and was therefore not included. Applying our multinomial model
to a training set consisting of 9 PN, 9 CL, and 11MES samples, we
found that 18 of the 29 (62.1%) samples were classified correctly.
MES samples were accurately predicted with a sensitivity of 90.9%
(Supplementary Table S3). The training set had less success with
the PN and CL subtypes (sensitivity of 55.5% and 33.3%,
respectively).
The test set was composed of 4 PN, 10 CL, and 7 MES
tumors. Of the 21 samples, 13 were classified correctly based
on the model (61.9%). The model accurately predicted the
majority of PN and MES samples (sensitivity PN: 100%, MES:
71.4%). CL tumors were successfully identified with
a sensitivity of only 40% (Supplementary Table S4). All esti-
mated specificity values were adequate. None of the biomar-
kers alone were significantly associated with subtype (P > .05,
Supplementary Table S5). These results highlight the potential
of this IHC-based model to predict GBM subtypes, but neces-
sitate additional studies with larger sample sizes.
IBA1+ TAM undergo morphological changes in the
peri-tumor area
Given the abundance of TAM in GBM, we further investigated
their morphology in relation to naïve microglial shape in the
adjacent brain (Figure 5). Four GBM samples displaying clear
core-tumor, peri-tumor, and non-tumor areas were selected.
Since five-micrometer sections were analyzed, the following data
represent relative values for the purposes of comparing the differ-
ent regions and underestimate the absolute number of microglial
processes, which extend in all three dimensions. For more com-
prehensive analyses and depictions of microglial processes, we
refer to previously published work.42–45
We measured the number of primary processes that extend
from TAM, since lower numbers are associated with
activation.46 The highest number of processes were noted in
adjacent tumor-free brain tissue, with an average of 2.2 pri-
mary processes per cell. Lower numbers were seen in the peri-
tumor area (1.6 primary processes/cell), while the lowest
numbers were noted within tumor tissue, with an average of
1.1 per cell (Figure 5(b)). The qualitative perception that the
degree of IBA1-positivity gradually increased when going
from normal brain to peritumoral brain to brain tumor was
confirmed by quantitation of IBA1-positive areas (non-tumor:
5.9%, peri-tumor: 8.7%, tumor: 19.9%) (Figure 5(c)). These
phenomena, indicating an increased activation and infiltration
of TAM in the tumor compared to the adjacent brain, was
further visualized by plot profiles of the changing staining
intensity in those regions (Figure 5(d)).
Finally, the percentage of IBA1-positive area in the adja-
cent brain tissue of eleven tumor samples was compared to
that of the five control brain samples in order to examine
possible differences in activation (Figure 5(e)). The difference
in their means, however, was not significant (naïve control
brains: 3.9%, non-tumor tissue of GBM samples: 4.5%).
Discussion
The present study provides evidence of marked differences in
the cellular immune profile amongst distinct GBM subtypes.
First, we analyzed TCGA gene expression data and found an
upregulation of AIF1, CD3G, and CD4, markers of TAM,
T-cells, and T-helper cells respectively, in the MES subgroup.
Our results reflect those found by Doucette et al., who identi-
fied an enrichment of both proinflammatory and immuno-
suppressive genes in the MES subtype compared to the PN
and CL groups by leveraging TCGA data. 29 It should be
noted that not all chains of CD3 are specific T cell markers,
with natural killer (NK) cells, for instance, being able to
express some CD3 subunits as well.47
Due to limitations associated with the use of high-
throughput sequencing techniques, we complemented our
initial findings with an immunohistochemical study of
immune cell infiltration, which identified increased levels of
TAM and T cells in MES GBM. An investigation of human
adult and pediatric astrocytomas by Engler et al. also demon-
strated higher numbers of TAM in MES GBM compared to
PN MES CL
Figure 4. Graphic illustration depicting the immune cell infiltration in PN, MES, and CL GBM. IBA-positive area and T cell infiltration are markedly increased in MES
tumors. Each circle represents an area of one mm2.
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non-MES tumors, albeit using unequal group sizes and with-
out distinguishing among the remaining groups, rendering
a definitive assessment difficult.39 In another study of
human PN and MES tumors, Beier et al. similarly showed
that TAM and CD8+ T cells preferentially infiltrate MES
tumors, 40 although low sample numbers were used and the
subtype was determined based on a combination of immuno-
histochemical markers, preventing a conclusive judgment to
be made. Although the same caveats apply to the findings of
Sørensen et al, who also demonstrated higher numbers of
TAM in MES GBM, 41 our own results combined with the
cited studies make a compelling case for a significantly
increased presence of TAM infiltration in MES tumors at
the protein level. However, using gene expression data, we
demonstrated opposite effects of AIF1 in PN and MES GBM,
with high expression levels of this marker of TAM leading to
a worse prognosis within the former subtype and conferring
a survival benefit in the latter, suggesting that high numbers
of TAM are not a predictor for patient survival when various
subtypes are compared.
With regard to T cell infiltration, the results from previous
publications are less conclusive. While Prins et al. demon-
strated increased levels of CD3+ and CD8+ cells in MES versus
PN tumors in a Phase I trial testing a dendritic cell vaccine, no
difference was found in the infiltration of CD4+ and CD8+
cells in a study by Han et al.26,48 Both studies, however,
applied different molecular classifications, with the former
referring to the subtypes proposed by Phillips et al. and the
latter grouping their samples according to the systematization
put forth by Verhaak et al.8,9 Leveraging robust group sizes
and focusing on the three subgroups for which strong mole-
cular underpinnings exist, the PN, MES and CL subtypes.11
we aimed to add clarity to the question of T cell infiltration
and demonstrated increased numbers of different T cell
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Figure 5. Tumor-associated macrophages (TAM) exhibit distinct morphologies in tumor and non-tumor regions. (a) Image of a GBM section with adjacent brain tissue
stained with IBA1. The black rectangles represent images captured to quantify differences in the morphology of TAM in non-tumor (left), peri-tumor (mid), and tumor
(right) areas, as well as changes in IBA1-positivity. Peri-tumor areas were defined as a field in which half of the area is non-tumor and the other half is tumor tissue
based on macrophage morphology and cellular density. Scale bar corresponds to a length of 10 millimeters. (b) The number of primary processes per IBA1+ cell,
a marker for macrophage shape and activation, changes incrementally from non-tumor to tumor areas. The data points represent average numbers of processes per
cell in each area of different tumors. (c) Quantification shows the percentage area covered by IBA1+ TAM gradually increases from non-tumor to tumor areas, with
each dot representing the average of one sample. Dunn´s multiple comparisons test was performed. (d) Plot profile demonstrating a gradual increase in relative IBA1
immunopositivity with increasing proximity to the tumor parenchyma. The solid dark blue line indicates mean intensity and the shades represent ± one standard
deviation (n = 4 independent samples). Examples of TAM highlight their morphological plasticity. The section below the plot profile exemplifies the areas used for
this analysis. Staining intensity increases from left (non-tumor) to right (tumor). The scale bar indicates a length of 100 micrometers. (e) Quantification of the
percentage of the IBA1-positive area in control brains and non-tumor areas adjacent to GBM indicated no significant difference. Dots represent averages of each
sample. Mann-Whitney U test was performed.
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populations in MES GBM. Nonetheless, limitations apply to
our indirect quantification of CD4+ T cell-infiltration by sub-
tracting CD8+ from CD3+ T cells, as this reduces accuracy in
samples that have very low to nearly zero infiltration of
T cells, and because a small number of CD3+ cells lack both
CD8 and CD4.49 In a study by Waziri et al. analyzing subsets
of CD3+CD56+ infiltrating T cells in GBM, which constituted
nearly half of all CD3+ T cells in that sample, CD4/CD8
double-negative T cells only accounted for less than 5% of
all CD3+CD56+ cells.50
Despite challenges associated with the use of gene expression
profiling studies, the plethora of previous evidence, in addition to
our own data, indicate a fundamentally distinct immune profile in
MES tumors. These results confirm the findings of Wang et al.,
who similarly identified an increased immune infiltration in MES
GBM in an analysis usingCIBERSORT in silico cytometry, which is
a computational approach to studying relative cell compositions of
tissues.30 They further demonstrated that tumors switching their
molecular subtype upon recurrence also change their immune
profile accordingly, which indicates the inclusion of recurrent
tumors in our study may not constitute a confounding variable.30
Although the role of TAM in glioma pathogenesis is well-
established,16,17 the individual effects of the two populations
subsumed under this term, microglia- and monocyte-derived
macrophages, remain contentious areas of investigation.
While some authors have reported microglia constitute the
majority of mononuclear cells in GBM,51 our data using
transgenic knock-in reporter mice indicate a clear predomi-
nance of monocyte-derived macrophages in PN tumors.52
Unpublished findings from our laboratory indicate that
microglia are predominant in MES GBM. Although in
mouse systems microglia and monocyte-derived macrophages
can be distinguished by using cell type-specific reporter mice,
this is not possible in human FFPE tumors specimens due to
the lack of cell type-specific IHC markers. Although a recent
study using GBM single-cell RNA sequencing proposed
unique genes to discriminate microglia from macrophages,
validation at the protein level was performed only on two
tumor samples by FACS. 53 An improved understanding of
the ratio of these cell types might offer clues regarding their
differential interactions with neoplastic cells and help explain
the survival differences seen in our TCGA analysis.
The prognostic value of infiltrating T cells in GBM is
equally controversial. While some studies indicate high
CD3+ and CD8+ T cell numbers are associated with prolonged
survival, others, such as Zhai et al. in their analysis of the role
of the immunosuppressive enzyme IDO1 in gliomas, found
high levels of these subpopulations as well as CD4 + T cells to
confer an unfavorable outcome.27,48,54–60 Several investiga-
tions have been dedicated to understanding the impact of
regulatory T cells on the survival of GBM patients, with the
majority not reporting any significant relationship.55,57,58
However, our own finding based on TCGA demonstrating
a survival advantage for patients with higher FOXP3 levels,
possibly indicating increased Treg cell infiltration, as well as
studies implicating high FOXP3+ T cell levels in poorer over-
all survival, highlight the need for further investigations, espe-
cially taking into account the heterogeneity of the Treg cell
population.56,59,61 Although controversy exists in the literature
regarding FOXP3 being expressed either by macrophages or
cancer cells,62 our results, together with published literature,
suggest that its expression is largely limited to CD4+ and
CD8+ T cells.56,57 In this context, our findings in a small
cohort indicating lower CD3+ and CD4+ T cell levels in
G-CIMP-positive GBM, which are associated with mutations
in isocitrate dehydrogenase 1 (IDH1) and improved survival,-
63 further demonstrate the complexity of T cell involvement.
This last finding echoes results by Amankulor et al., who
identified lower levels of macrophages, T and B cells in
a small group of IDH1-mutated grade 2 and 3 gliomas,
which, the authors speculate, could potentially contribute to
the favorable outcome seen in G-CIMP tumors. 64
The advent of immune-based therapies for GBM has ren-
dered these questions increasingly pertinent. In their Phase I trial
of lysate-pulsed dendritic cells in the treatment of GBM, Prins
et al. identified a survival advantage for MES tumors.26
Interestingly, leveraging their high-throughput approach,
Wang et al. demonstrated an increased enrichment of genes
related to dendritic cells in the CL subtype, indicating these
tumors might benefit from the vaccine. Although the trial was
not designed to assess efficacy, it provides a rationale for con-
tinued investigations into the role of the immune system in the
context of molecular and cellular heterogeneity.65 The success of
immune checkpoint inhibitors in other cancer types such as
melanoma or lung cancer has generated interest in these agents
as a possible treatment option for GBM patients.66,67 Expression
of Programmed Death-Ligand 1 (PD-L1) has been shown to be
increased in tumors with a MES profile.68 Worse outcomes have
been observed in a correlative study in tumors with higher PD-
L1 expression, however a similar previous investigation had not
detected a difference in survival.69,70 Preclinical studies have
demonstrated significant survival advantages in mice treated
with inhibitors of PD-1 or PD-L1. 71,72 Clinical trials, however,
have thus far delivered mixed results.73,74 Consequently, addi-
tional investigations, which take into account the immune het-
erogeneity laid out in this study, seem warranted.
All of these findings demonstrate the potential of stratifica-
tion for GBM patients, creating the necessity to translate the
subtypes into clinical applications. Molecular characterization,
however, is still costly and dependent upon the existence of
appropriate facilities. Therefore, we propose a model based on
distinct immune cell infiltration patterns that is able to identify
MES tumors with a high sensitivity. However, it should be noted,
owing to the relatively small sample size used to establish the
model, further validation is required. Since the study used
archived clinical FFPE specimens, there is significant potential
for developing the model to increase the sensitivity of prediction,
with the ultimate goal of creating a prognostic model.
In conclusion, our results lend credence to the notion of
utterly distinct microenvironments of molecularly heteroge-
neous GBM subtypes and form the basis for future mechan-
istic studies investigating their relevance in the context of
novel therapeutic strategies and GBM pathogenesis.
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